FDA proposes Rx label revisions for moms

Share this article:

The FDA on Wednesday announced it is proposing revisions to physician labeling for Rx drugs to include more info about their use by pregnant and/or breast-feeding mothers.

The proposed changes would give physicians more comprehensive information for making prescribing decisions and for counseling mothers and moms-to-be about medications, the agency said in a posting on its Web site.

“With this proposal, FDA's goal is to help women, their physicians and their pharmacists have better information about the effects of prescription medicines so that pregnant women, nursing mothers, and breast-feeding infants will benefit,” said Sandra Kweder of the FDA's Center for Drug Evaluation and Research.

The agency is soliciting electronic comments regarding the proposal over the next 90 days via the Federal Documents Management System/eRulemaking portal a www.regulations.govThe FDA said it will carefully consider the comments in preparing a final rule.

More information on the FDA proposal is available at: http://www.fda.gov/cder/regulatory/pregnancy_labeling/default.htm.

 

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.